Patents by Inventor Gary Clawson
Gary Clawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210338705Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: June 9, 2021Publication date: November 4, 2021Inventors: James H. Adair, Gail L. Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Xiaomeng Tang, Gary A. Clawson, Jill P. Smith, Tye Deering
-
ENCAPSULATION AND HIGH LOADING EFFICIENCY OF PHOSPHORYLATED DRUG AND IMAGING AGENTS IN NANOPARTICLES
Publication number: 20190255087Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: April 12, 2019Publication date: August 22, 2019Inventors: James H. Adair, Gail L. Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Xiaomeng Tang, Gary A. Clawson, Jill P. Smith, Tye Deering -
ENCAPSULATION AND HIGH LOADING EFFICIENCY OF PHOSPHORYLATED DRUG AND IMAGING AGENTS IN NANOPARTICLES
Publication number: 20170209478Abstract: Method of producing nanoparticle of drug and imaging agents are provided. The phosphorylated encapsulated drugs and imaging agents could be encapsulated at therapeutic levels, were encapsulated at higher amounts. The CPSNPs were more effective in treating cancer, in reducing cancer proliferation, arresting cancer cell growth than when not in the form of a CPSNP, and showed efficacious treatment of cancer cells at far lower dosage than free molecules. Calcium phosphosilicate and phosphate nanoparticles are disclosed and their method of use. The methods and nanoparticles are particularly efficacious where CPSNPs were used to encapsulate 5-FU metabolites such as FdUMP and gemcitabine metabolites.Type: ApplicationFiled: January 20, 2017Publication date: July 27, 2017Inventors: James H. Adair, Gail Matters, Welley S. Loc, Amra Tabakovic, Mark Kester, Sam Linton, Christopher McGovern, Christopher Gigliotti, Xiaomeng Tang, Peter J. Butler, Gary A. Clawson, Jill P. Smith -
Patent number: 7732197Abstract: The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5? and/or 3? autocatalytically cleaving ribozymes.Type: GrantFiled: February 26, 2002Date of Patent: June 8, 2010Assignees: The Penn State Research Foundation, MUSC Foundation for Research DevelopmentInventors: James S. Norris, Gary A. Clawson, Michael G. Schmidt, Brian Hoel, Wei-Hua Pan, Joseph W. Dolan
-
Patent number: 7704965Abstract: The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers).Type: GrantFiled: June 26, 2003Date of Patent: April 27, 2010Assignee: The Penn State Research FoundationInventors: Gary A. Clawson, Wei-Hua Pan, Diane Thiboutot, Neil Christensen
-
Publication number: 20100036107Abstract: The invention provides isolated nucleic acids. For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense and antisense sequences that are complementary to each other. In addition, the invention provides cells, viruses, and transgenic animals (e.g., transgenic non-human animals) containing one or more of the isolated nucleic acids provided herein as well as methods for using one or more of the isolated nucleic acids provided herein to reduce the level of an RNA (e.g., an mRNA) within a cell.Type: ApplicationFiled: October 13, 2009Publication date: February 11, 2010Inventors: Gary A. Clawson, Wei-Hua Pan, Ping Xin
-
Patent number: 7575918Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: GrantFiled: September 8, 2004Date of Patent: August 18, 2009Assignee: The Penn State Research FoundationInventors: James Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael G. Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan
-
Patent number: 7402561Abstract: In the US about ? of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.Type: GrantFiled: March 9, 2005Date of Patent: July 22, 2008Assignee: Clawnor, Inc.Inventors: Gary Clawson, Craig Meyers, David Drubin, Molly McLaughlin-Drubin
-
Publication number: 20060269530Abstract: The invention provides isolated nucleic acids. For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense and antisense sequences that are complementary to each other. In addition, the invention provides cells, viruses, and transgenic animals (e.g., transgenic non-human animals) containing one or more of the isolated nucleic acids provided herein as well as methods for using one or more of the isolated nucleic acids provided herein to reduce the level of an RNA (e.g., an mRNA) within a cell.Type: ApplicationFiled: February 23, 2004Publication date: November 30, 2006Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Gary Clawson, Wei-Hua Pan, Ping Xin
-
Publication number: 20060223774Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: ApplicationFiled: March 13, 2006Publication date: October 5, 2006Inventors: James Norris, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Gary Clawson, Wei-Hua Pan
-
Publication number: 20060058252Abstract: The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers).Type: ApplicationFiled: June 26, 2003Publication date: March 16, 2006Inventors: Gary Clawson, Wei-Hua Pan, Diane Thiboutot, Neil Christensen
-
Publication number: 20050209150Abstract: In the US about ? of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.Type: ApplicationFiled: March 9, 2005Publication date: September 22, 2005Inventors: Gary Clawson, Craig Meyers, David Drubin, Molly McLaughlin-Drubin
-
Publication number: 20050107326Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: ApplicationFiled: September 8, 2004Publication date: May 19, 2005Inventors: James Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan
-
Publication number: 20040220123Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agent to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: ApplicationFiled: May 27, 2003Publication date: November 4, 2004Inventors: James S. Norris, Caroline Westwater, David A. Schofield, Michael G. Schmidt, Brian D. Hoel, Joseph W. Dolan, Gary A. Clawson, Wei-Hua Pan
-
Publication number: 20040209263Abstract: The invention provides improved library selection procedures for nucleic acids which allow the rapid determination of accessible target sites throughout relatively long target RNAs. This invention provides an improved method of screening a library of nucleic acids to identify cleavage sites of a target RNA. The steps of the screening comprise generating the library of nucleic acids, wherein each nucleic acid comprises a catalytic core flanked by random nucleotides; adding said target RNA to the library of nucleic acids; and isolating nucleic acids that cleave said target RNA. The nucleic acids selected by the methods described herein are also provided in the invention.Type: ApplicationFiled: February 6, 2004Publication date: October 21, 2004Inventors: Gary A. Clawson, Wei-Hua Pan
-
Publication number: 20030125280Abstract: The invention provides compositions comprising the tissue specific and target RNA-specific ribozyme(s) in either a viral delivery system or a biologic liposome preparation, wherein the viral delivery system or a biologic liposome comprises a pathogen-specific promotor upstream from a sequence encoding a triple ribozyme comprising a) a 5′ autocatalytically cleaving ribozyme sequence, b) a catalytic ribozyme comprising a target RNA-specific binding site and c) a 3′ autocatalytically cleaving ribozyme sequence. The invention also provides methods of treating and/or preventing bacterial infections by administering the compositions of the invention.Type: ApplicationFiled: April 19, 2002Publication date: July 3, 2003Applicants: Medical University of South Carolina, The Penn State Research Foundation, a Pennsylvania corporationInventors: James S. Norris, Michael G. Schmidt, Joseph W. Dolan, Steven D. London, Harold D. May, Gary A. Clawson
-
Publication number: 20030092651Abstract: The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5′ and/or 3′ autocatalytically cleaving ribozymes.Type: ApplicationFiled: February 26, 2002Publication date: May 15, 2003Applicant: Medical University of South Carolina, an agency of the State of South CarolinaInventors: James S. Norris, Gary A. Clawson, Michael G. Schmidt, Brian Hoel, Wei-Hua Pan, Joseph W. Dolan, David Schofield, Caroline Westwater, Cancan Huang
-
Patent number: 6271359Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: GrantFiled: April 14, 1999Date of Patent: August 7, 2001Assignees: MUSC Foundation for Research Development, The Penn State Research FoundationInventors: James Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan
-
Patent number: 5824519Abstract: The invention provides tissue-specific and target RNA-specific ribozymes. These ribozymes can be used to destroy target-specific neoplasms and to treat viral infections, among other uses. The ribozymes of the present invention comprise a 5' autocatalytically cleaving ribozyme sequence, a catalytic ribozyme comprising a target RNA-specific binding site and a 3' autocatalytically cleaving ribozyme. The invention also provides nucleic acids which encode the ribozymes of the invention. These nucleic acids can be used to express the ribozymes of the invention at the selected site. Methods of treating disease by administering the ribozymes are provided.Type: GrantFiled: November 8, 1995Date of Patent: October 20, 1998Assignee: Medical University of South CarolinaInventors: James S. Norris, Gary A. Clawson